

CGA/17/51 – Leveraging the 25 year follow-up of the WOSCOPS trial

Two pivotal trials conducted in Scotland (WOSCOPS and PROSPER) showed the beneficial effects of lowering cholesterol in men who had not had a heart attack and in the elderly. Long-term follow-up in WOSCOPS showed additional benefits in reducing heart disease. We will extend follow-up to 25 years in WOSCOPS and 15 years in PROSPER. We will apply for funding to explore long-term benefits in the peripheral arteries and in heart failure and to develop risk models for coronary heart disease, heart failure and peripheral artery disease, using clinical, laboratory and genetic information. We will also study the natural history of vascular disease in these populations.